Skip to main content

Laboratory Investigation in CDH

  • Chapter
  • First Online:
Chronic Headache

Abstract

It is important to ensure that the patient with chronic daily headache has had a thorough evaluation to rule out secondary causes of headache. This includes the use of laboratory studies on serum as well as cerebral spinal fluid (CSF). In this chapter we will walk through the appropriate evaluation in the emergency department as well as the outpatient setting starting with serology, then CSF, and genetic testing. We will end with a discussion of special cases, including pregnancy, immunocompromised patient, traumatic brain injury, and hypercoagulability states.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 79.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 129.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. George JN, et al. Drug-induced thrombocytopenia: a systematic review of published case reports. Ann Intern Med. 1998;129(11):886–90.

    Article  CAS  PubMed  Google Scholar 

  2. Chang CY, Schiano TD. Review article: drug hepatotoxicity. Aliment Pharmacol Ther. 2007;25(10):1135–51.

    Article  CAS  PubMed  Google Scholar 

  3. Tietjen GE, Collins SA. Hypercoagulability and migraine. Headache. 2017;58(1):173–83.

    Article  PubMed  Google Scholar 

  4. Zakharova MY, et al. Risk factors for heart attack, stroke, and venous thrombosis associated with hormonal contraceptive use. Clin Appl Thromb Hemost. 2011;17(4):323–31.

    Article  CAS  PubMed  Google Scholar 

  5. Miyakis S, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006;4(2):295–306.

    Article  CAS  PubMed  Google Scholar 

  6. Coutinho JM, et al. Cerebral venous and sinus thrombosis in women. Stroke. 2009;40(7):2356–61.

    Article  PubMed  Google Scholar 

  7. Crassard I, et al. A negative D-dimer assay does not rule out cerebral venous thrombosis: a series of seventy-three patients. Stroke. 2005;36(8):1716–9.

    Article  PubMed  Google Scholar 

  8. Alons IM, et al. D-dimer for the exclusion of cerebral venous thrombosis: a meta-analysis of low risk patients with isolated headache. BMC Neurol. 2015;15:118.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Kudva YC, Sawka AM, Young WF Jr. Clinical review 164: the laboratory diagnosis of adrenal pheochromocytoma: the Mayo Clinic experience. J Clin Endocrinol Metab. 2003;88(10):4533–9.

    Article  CAS  PubMed  Google Scholar 

  10. Loder E, Cardona L. Evaluation for secondary causes of headache: the role of blood and urine testing. Headache. 2011;51(2):338–45.

    Article  PubMed  Google Scholar 

  11. Headache Classification Committee of the International Headache Society (IHS). The international classification of headache disorders, 3rd edition (beta version). Cephalalgia. 2013;33(9):629–808.

    Article  Google Scholar 

  12. Hunder GG, et al. The American college of rheumatology 1990 criteria for the classification of giant cell arteritis. Arthritis Rheum. 1990;33(8):1122–8.

    Article  CAS  PubMed  Google Scholar 

  13. Miller A, Green M, Robinson D. Simple rule for calculating normal erythrocyte sedimentation rate. Br Med J (Clin Res Ed). 1983;286(6361):266.

    Article  CAS  Google Scholar 

  14. Hayreh SS, et al. Giant cell arteritis: validity and reliability of various diagnostic criteria. Am J Ophthalmol. 1997;123(3):285–96.

    Article  CAS  PubMed  Google Scholar 

  15. Levin M, Ward TN. Horton's disease: past and present. Curr Pain Headache Rep. 2005;9(4):259–63.

    Article  PubMed  Google Scholar 

  16. Nye BL, Ward TN. Clinic and emergency room evaluation and testing of headache. Headache. 2015;55(9):1301–8.

    Article  PubMed  Google Scholar 

  17. Costello F, et al. Role of thrombocytosis in diagnosis of giant cell arteritis and differentiation of arteritic from non-arteritic anterior ischemic optic neuropathy. Eur J Ophthalmol. 2004;14(3):245–57.

    Article  CAS  PubMed  Google Scholar 

  18. Parikh M, et al. Prevalence of a normal C-reactive protein with an elevated erythrocyte sedimentation rate in biopsy-proven giant cell arteritis. Ophthalmology. 2006;113(10):1842–5.

    Article  PubMed  Google Scholar 

  19. Mayer M, et al. Antiphospholipid syndrome and central nervous system. Clin Neurol Neurosurg. 2010;112(7):602–8.

    Article  PubMed  Google Scholar 

  20. Glueck CJ, et al. Idiopathic intracranial hypertension: associations with coagulation disorders and polycystic-ovary syndrome. J Lab Clin Med. 2003;142(1):35–45.

    Article  CAS  PubMed  Google Scholar 

  21. Kim JM, et al. Idiopathic intracranial hypertension as a significant cause of intractable headache in patients with systemic lupus erythematosus: a 15-year experience. Lupus. 2012;21(5):542–7.

    Article  PubMed  Google Scholar 

  22. Tse C, Klein R. Intracranial hypertension associated with systemic lupus erythematosus in a young male patient. Lupus. 2013;22(2):205–12.

    Article  CAS  PubMed  Google Scholar 

  23. Dhungana S, Sharrack B, Woodroofe N. Idiopathic intracranial hypertension. Acta Neurol Scand. 2010;121(2):71–82.

    Article  CAS  PubMed  Google Scholar 

  24. Hanly JG, et al. Headache in systemic lupus erythematosus: results from a prospective, international inception cohort study. Arthritis Rheum. 2013;65(11):2887–97.

    Article  PubMed  Google Scholar 

  25. Galli M. Clinical utility of laboratory tests used to identify antiphospholipid antibodies and to diagnose the antiphospholipid syndrome. Semin Thromb Hemost. 2008;34(4):329–34.

    Article  CAS  PubMed  Google Scholar 

  26. Singh SK. Prevalence of migraine in hypothyroidism. J Assoc Physicians India. 2002;50:1455–6.

    PubMed  CAS  Google Scholar 

  27. Moreau T, et al. Headache in hypothyroidism. Prevalence and outcome under thyroid hormone therapy. Cephalalgia. 1998;18(10):687–9.

    Article  CAS  PubMed  Google Scholar 

  28. Lima Carvalho MF, de Medeiros JS, Valenca MM. Headache in recent onset hypothyroidism: prevalence, characteristics and outcome after treatment with levothyroxine. Cephalalgia. 2016;37(10):938–46.

    Article  PubMed  Google Scholar 

  29. Iwasaki Y, et al. Thyroid function in patients with chronic headache. Int J Neurosci. 1991;57(3–4):263–7.

    Article  CAS  PubMed  Google Scholar 

  30. Amy JR. Tests of thyroid function in chronic headache patients. Headache. 1987;27(6):351–3.

    Article  CAS  PubMed  Google Scholar 

  31. Hagen K, et al. Low headache prevalence amongst women with high TSH values. Eur J Neurol. 2001;8(6):693–9.

    Article  CAS  PubMed  Google Scholar 

  32. Martin AT, et al. Headache disorders may be a risk factor for the development of new onset hypothyroidism. Headache. 2017;57(1):21–30.

    Article  PubMed  Google Scholar 

  33. Surks MI, et al. Subclinical thyroid disease: scientific review and guidelines for diagnosis and management. JAMA. 2004;291(2):228–38.

    Article  CAS  PubMed  Google Scholar 

  34. Miraglia CM. A review of the centers for disease control and prevention's guidelines for the clinical laboratory diagnosis of Lyme disease. J Chiropr Med. 2016;15(4):272–80.

    Article  PubMed  PubMed Central  Google Scholar 

  35. Understanding the EIA Test| Lyme Disease | CDC. [cited 2017 May 16]; Available from: https://www.cdc.gov/lyme/diagnosistesting/labtest/twostep/eia/index.htm.

  36. Dressler F, et al. Western blotting in the serodiagnosis of Lyme disease. J Infect Dis. 1993;167(2):392–400.

    Article  CAS  PubMed  Google Scholar 

  37. Two-step laboratory testing process| lyme disease | CDC. [cited 2017 May 16]; Available from: https://www.cdc.gov/lyme/diagnosistesting/labtest/twostep/.

  38. Notice to Readers Recommendations for Test Performance and Interpretation from the Second National Conference on Serologic Diagnosis of Lyme Disease. [cited 2017 May 16]; Available from: https://www.cdc.gov/mmwr/preview/mmwrhtml/00038469.htm.

  39. Hinckley AF, et al. Lyme disease testing by large commercial laboratories in the United States. Clin Infect Dis. 2014;59(5):676–81.

    Article  PubMed  Google Scholar 

  40. Aucott J, et al. Diagnostic challenges of early Lyme disease: lessons from a community case series. BMC Infect Dis. 2009;9:79.

    Article  PubMed  PubMed Central  Google Scholar 

  41. Aguero-Rosenfeld ME, et al. Evolution of the serologic response to Borrelia burgdorferi in treated patients with culture-confirmed erythema migrans. J Clin Microbiol. 1996;34(1):1–9.

    PubMed  PubMed Central  CAS  Google Scholar 

  42. Lyme Disease | 2017 Case Definition. [cited 2017 May 16]; Available from: /nndss/conditions/lyme-disease/case-definition/2017/.

    Google Scholar 

  43. Ridzon R, et al. Simultaneous transmission of human immunodeficiency virus and hepatitis C virus from a needle-stick injury. N Engl J Med. 1997;336(13):919–22.

    Article  CAS  PubMed  Google Scholar 

  44. Robb ML, et al. Prospective study of acute HIV-1 infection in adults in East Africa and Thailand. N Engl J Med. 2016;374(22):2120–30.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Ho DD, et al. Isolation of HTLV-III from cerebrospinal fluid and neural tissues of patients with neurologic syndromes related to the acquired immunodeficiency syndrome. N Engl J Med. 1985;313(24):1493–7.

    Article  CAS  PubMed  Google Scholar 

  46. Schacker T, et al. CLinical and epidemiologic features of primary hiv infection. Ann Intern Med. 1996;125(4):257–64.

    Article  CAS  PubMed  Google Scholar 

  47. HIV Among Gay and Bisexual Men. 2017; Available from: https://www.cdc.gov/hiv/group/msm/index.html.

  48. Reichman EF, Polglaze K, Euerle B. Neurological and neurosurgical procedures: lumbar puncture. In: Emergency medicine procedures. New York: McGraw Hill; 2013. p. 747–61.

    Google Scholar 

  49. Lee SC, Lueck CJ. Cerebrospinal fluid pressure in adults. J Neuroophthalmol. 2014;34(3):278–83.

    Article  CAS  PubMed  Google Scholar 

  50. Whiteley W, et al. CSF opening pressure: reference interval and the effect of body mass index. Neurology. 2006;67(9):1690–1.

    Article  CAS  PubMed  Google Scholar 

  51. Friedman DI, Liu GT, Digre KB. Revised diagnostic criteria for the pseudotumor cerebri syndrome in adults and children. Neurology. 2013;81(13):1159–65.

    Article  PubMed  Google Scholar 

  52. Stern BJ, et al. Sarcoidosis and its neurological manifestations. Arch Neurol. 1985;42(9):909–17.

    Article  CAS  PubMed  Google Scholar 

  53. O'Connell K, et al. Neurosarcoidosis: clinical presentations and changing treatment patterns in an Irish Caucasian population. Ir J Med Sci. 2017;186(3):759–66.

    Article  CAS  PubMed  Google Scholar 

  54. Joseph FG, Scolding NJ. Neurosarcoidosis: a study of 30 new cases. J Neurol Neurosurg Psychiatry. 2009;80(3):297–304.

    Article  CAS  PubMed  Google Scholar 

  55. Kaplan JG, et al. Leptomeningeal metastases: comparison of clinical features and laboratory data of solid tumors, lymphomas and leukemias. J Neuro-Oncol. 1990;9(3):225–9.

    Article  CAS  Google Scholar 

  56. Glantz MJ, et al. Cerebrospinal fluid cytology in patients with cancer: minimizing false-negative results. Cancer. 1998;82(4):733–9.

    Article  CAS  PubMed  Google Scholar 

  57. Rozen T, Swidan SZ. Elevation of CSF tumor necrosis factor alpha levels in new daily persistent headache and treatment refractory chronic migraine. Headache. 2007;47(7):1050–5.

    Article  PubMed  Google Scholar 

  58. Saxon A. CSF TNFalpha has not been shown to be elevated in headache patients. Headache. 2015;55(9):1266.

    Article  PubMed  Google Scholar 

  59. Rozen TD. TNF-alpha has not been shown to be elevated in headache patients: a response. Headache. 2015;55(9):1267.

    Article  PubMed  Google Scholar 

  60. Rozen TD, Beams JL. New daily persistent headache with a thunderclap headache onset and complete response to nimodipine (a new distinct subtype of NDPH). J Headache Pain. 2013;14:100.

    Article  PubMed  PubMed Central  Google Scholar 

  61. Terlizzi R, et al. P037. Headache in multiple sclerosis: prevalence and clinical features in a case control-study. J Headache Pain. 2015;16(Suppl 1):A83.

    Article  PubMed  PubMed Central  Google Scholar 

  62. Huss AM, et al. Importance of cerebrospinal fluid analysis in the era of McDonald 2010 criteria: a German-Austrian retrospective multicenter study in patients with a clinically isolated syndrome. J Neurol. 2016;263(12):2499–504.

    Article  PubMed  PubMed Central  Google Scholar 

  63. Lim ET, et al. Anti-myelin antibodies do not allow earlier diagnosis of multiple sclerosis. Mult Scler. 2005;11(4):492–4.

    Article  CAS  PubMed  Google Scholar 

  64. Maksemous N, et al. Targeted next generation sequencing identifies novel NOTCH3 gene mutations in CADASIL diagnostics patients. Hum Genomics. 2016;10(1):38.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  65. Liem MK, et al. CADASIL and migraine: a narrative review. Cephalalgia. 2010;30(11):1284–9.

    Article  PubMed  Google Scholar 

  66. Guey S, et al. Prevalence and characteristics of migraine in CADASIL. Cephalalgia. 2015;36(11):1038–47.

    Article  Google Scholar 

  67. Essmeister R, et al. MTHFR and ACE polymorphisms do not increase susceptibility to migraine neither alone nor in combination. Headache. 2016;56(8):1267–73.

    Article  PubMed  Google Scholar 

  68. Lea RA, et al. Genetic variants of angiotensin converting enzyme and methylenetetrahydrofolate reductase may act in combination to increase migraine susceptibility. Brain Res Mol Brain Res. 2005;136(1–2):112–7.

    Article  CAS  PubMed  Google Scholar 

  69. Pavlakis SG, et al. Mitochondrial myopathy, encephalopathy, lactic acidosis, and strokelike episodes: a distinctive clinical syndrome. Ann Neurol. 1984;16(4):481–8.

    Article  CAS  PubMed  Google Scholar 

  70. Montagna P, et al. MELAS syndrome: characteristic migrainous and epileptic features and maternal transmission. Neurology. 1988;38(5):751–4.

    Article  CAS  PubMed  Google Scholar 

  71. Ohno K, Isotani E, Hirakawa K. MELAS presenting as migraine complicated by stroke: case report. Neuroradiology. 1997;39(11):781–4.

    Article  CAS  PubMed  Google Scholar 

  72. Koenig MK, et al. Recommendations for the management of strokelike episodes in patients with mitochondrial encephalomyopathy, lactic acidosis, and strokelike episodes. JAMA Neurol. 2016;73(5):591–4.

    Article  PubMed  Google Scholar 

  73. Kaufmann P, et al. Natural history of MELAS associated with mitochondrial DNA m.3243A>G genotype. Neurology. 2011;77(22):1965–71.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  74. Sunde K, et al. Case report: 5 year follow-up of adult late-onset mitochondrial encephalomyopathy with lactic acid and stroke-like episodes (MELAS). Mol Genet Metab Rep. 2016;9:94–7.

    Article  PubMed  PubMed Central  Google Scholar 

  75. Ophoff RA, et al. Familial hemiplegic migraine and episodic ataxia type-2 are caused by mutations in the Ca2+ channel gene CACNL1A4. Cell. 1996;87(3):543–52.

    Article  CAS  PubMed  Google Scholar 

  76. Russell MB, Ducros A. Sporadic and familial hemiplegic migraine: pathophysiological mechanisms, clinical characteristics, diagnosis, and management. Lancet Neurol. 2011;10(5):457–70.

    Article  PubMed  Google Scholar 

  77. Thomsen LL, et al. The genetic spectrum of a population-based sample of familial hemiplegic migraine. Brain. 2007;130(Pt 2):346–56.

    Article  CAS  PubMed  Google Scholar 

  78. Ducros A, et al. The clinical spectrum of familial hemiplegic migraine associated with mutations in a neuronal calcium channel. N Engl J Med. 2001;345(1):17–24.

    Article  CAS  PubMed  Google Scholar 

  79. De Fusco M, et al. Haploinsufficiency of ATP1A2 encoding the Na+/K+ pump alpha2 subunit associated with familial hemiplegic migraine type 2. Nat Genet. 2003;33(2):192–6.

    Article  CAS  PubMed  Google Scholar 

  80. Ambrosini A, et al. Familial basilar migraine associated with a new mutation in the ATP1A2 gene. Neurology. 2005;65(11):1826–8.

    Article  CAS  PubMed  Google Scholar 

  81. Jurkat-Rott K, et al. Variability of familial hemiplegic migraine with novel A1A2 Na+/K+-ATPase variants. Neurology. 2004;62(10):1857–61.

    Article  CAS  PubMed  Google Scholar 

  82. Dichgans M, et al. Mutation in the neuronal voltage-gated sodium channel SCN1A in familial hemiplegic migraine. Lancet. 2005;366(9483):371–7.

    Article  CAS  PubMed  Google Scholar 

  83. Thomsen LL, et al. Screen for CACNA1A and ATP1A2 mutations in sporadic hemiplegic migraine patients. Cephalalgia. 2008;28(9):914–21.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Barbara L. Nye .

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer International Publishing AG, part of Springer Nature

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Saunders, B.J., Aberkorn, I.S., Nye, B.L. (2019). Laboratory Investigation in CDH. In: Green, M., Cowan, R., Freitag, F. (eds) Chronic Headache. Springer, Cham. https://doi.org/10.1007/978-3-319-91491-6_12

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-91491-6_12

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-91490-9

  • Online ISBN: 978-3-319-91491-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics